A Phase 1 Trial of MLN8237 Plus Romidepsin for Relapsed/Refractory Aggressive B-cell and T-cell Lymphomas

Trial Profile

A Phase 1 Trial of MLN8237 Plus Romidepsin for Relapsed/Refractory Aggressive B-cell and T-cell Lymphomas

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Alisertib (Primary) ; Romidepsin
  • Indications B cell lymphoma; Burkitt's lymphoma; Follicular lymphoma; Hairy cell leukaemia; Hodgkin's disease; Mantle-cell lymphoma; Peripheral T-cell lymphoma; T cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Jun 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Jul 2017.
    • 08 Dec 2015 Interim results (n=12) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 28 Sep 2015 According to ClinicalTrials.gov record, the primary endpoint and the treatment table has been amended to include different dose levels
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top